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Abstract
Purpose To test whether improvement in glycosylated
haemoglobin (HbA1c) as a marker of glycaemic control,
following intensifying insulin therapy, is associated with
improvements in HRQoL.
Methods Dutch sub-optimally controlled (HbA1c [ 7%)
type 2 diabetes patients (N = 447, mean age 59 ± 11)
initiated insulin glargine therapy. Data were collected at
baseline, 3 and 6 months, and included HbA1c and measures
of HRQoL: diabetes symptom distress (Diabetes Symptom
Checklist-revised; DSC-r), fear of hypoglycaemia (Hypo-
glycaemia Fear Survey; HFS-w) and emotional well-being
(WHO-5 wellbeing index).
Results HbA1c decreased from 8.8 ± 1.4% to 8.0 ± 1.2%
and 7.7 ± 1.3% at 3 and 6 months follow-up, respectively
(P \ 0.001), DSC-r score improved from 17.7 ± 14.7 to
14.3 ± 13.3 and 13.6 ± 13.3 (P \ 0.001). HFS-w score
did not significantly change. WHO-5 score increased from
56 ± 23 to 62 ± 23 and 65 ± 22 P \ 0.001). A modest,
significant association was found between HbA1c and
WHO-5 score (B = -1.8, 95% CI: -2.7 to -0.8) and
HbA1c and DSC-r score (B = 1.0, 95% CI: 0.4 to 1.6).
No such association was found for HFS-w score.
Conclusions An association between improvement in
HbA1c by means of optimising insulin therapy and
improvement in HRQoL in type 2 diabetes patients has
been observed. A weak, yet significant longitudinal asso-
ciation was found between improved HbA1c and emotional
well-being and diabetes symptom distress.
Keywords Type 2 diabetes mellitus  Insulin glargine 
Glycaemic control  Quality of life  Emotional well-being
Introduction
It is estimated that worldwide 220 million people have type
2 diabetes mellitus [1], a chronic illness characterised by
hyperglycaemia due to insulin resistance and beta-cell
dysfunction. Diabetes is a burdensome disease that can
seriously impair the quality of life of patients and is
accompanied by huge economical costs mainly caused by
debilitating micro- and macrovascular complications [2].
Hyperglycaemia plays a crucial role in the pathogenesis
of diabetes-related complications [2]. Diabetes treatment
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should therefore aim for optimal glycaemic control (usu-
ally defined as HbA1c B 7%), while preserving patients’
quality of life [3, 4]. To this end, different pharmacological
interventions are available. Due to progressive beta-cell
failure, most type 2 diabetes patients will require insulin
therapy at some point [4], exposing them to an increased
risk of hypoglycaemia and death [5, 6].
In the past, NPH (Neutral Protamine Hagedorn) insulin was
commonly used as long-acting insulin, which has a pro-
nounced insulin peak 4–8 h post-injection. In the past dec-
ades, so-called long-acting basal insulin analogues, insulin
glargine and insulin detemir, have been developed. Such
insulins are relatively easy to use and have a prolonged,
consistent duration of action, covering 18–24 h, with low rates
of hypoglycaemia [7]. Favourable effects on health-related
quality of life (HRQoL) have been reported after initiation of
long-acting insulin therapy [7, 8], but evidence is scarce.
While a modest association has been found between
depression and higher HbA1c [9], an important question in the
context of diabetes treatment that remains unresolved pertains
to the relationship between glycaemic control and patients’
HRQoL. Improved glycaemic control can directly positively
affect HRQoL by reducing burdensome symptoms, such as
fatigue, cognitive distress and blurred vision, and indirectly by
reduced worries about secondary diabetes complications, the
presence of which is being regarded as the largest threat to
HRQoL in patients with diabetes [10, 11]. On the other hand,
stricter glycaemic control can also negatively affect HRQoL
due to a higher risk of hypoglycaemia and concomitant anx-
ieties [12]. A landmark study in type 2 diabetes, the United
Kingdom Prospective Diabetes Study (UKPDS) has shown
that optimisation of treatment with the aim to achieve strict
glycaemic control did not negatively affect patients’ well-
being. However, the experience of severe hypoglycaemic
episodes was found to be related to a deterioration of quality of
life, particularly in the domain of mood [13].
Another study into the relationship between glycaemic
control and HRQoL in older male type 2 diabetes patients
found no cross-sectional or longitudinal relation [14].
However, a Dutch cross-sectional study did find a corre-
lation between HbA1c and mood status (r = 0.23,
P \ 0.01) [15]. This study also used a diabetes-specific
measure (diabetes symptom distress), which showed a
negative association with better glycaemic control, i.e. less
symptom burden with lower HbA1c (-1 point on DSC-r
score for each per cent of HbA1c reduction). In addition,
improving glycaemic control in sub-optimally controlled
type 2 diabetes patients on oral medication has been
demonstrated to improve quality of life, which was defined
by the authors as 5 visual analogue scales: perceived
health, mental and emotional health, self reported cognitive
function, general health perceptions and symptom distress.
Patients improved 0.2 SD on the sum of these scales [16].
To date, research examining the relationship between
(improving) glycaemic control and HRQoL is limited and
inconsistent. Therefore, we set out to study the relationship
between glycaemic control and HRQoL in type 2 diabetes.
Data were derived from an observational cohort study
carried out in the Netherlands, aimed to study the impact of




In the present analysis, data from the observational ESPRIT
(Effect Study on Patient-Reported outcomes in Insulin
glargine Treatment) study were used. The study was con-
ducted between 2005 and 2008 in the Netherlands. In this
study, diabetes specialists invited patients with type 2 dia-
betes who were in sub-optimal control (HbA1c [ 7%) to
participate. Inclusion criteria were: type 2 diabetes mellitus,
an age of 18 years or older, current treatment with basal
insulin and a clinical need to initiate insulin glargine. The
decision to initiate treatment with insulin glargine as basal
therapy was made at the discretion of the treating diabetes
specialist. The study did not interfere with clinical practice
and only included filling out a questionnaire booklet that
took about 15 min at three consecutive periodic consulta-
tions. The questionnaire booklet was provided to the patient
by the treating physician. Clinical data were retrieved from
the medical chart. In view of the observational and non-
invasive nature, the present study was not subject to the
Dutch Medical Research Involving Human Subjects Act.
Standardised study information and informed consent were
provided to all patients and diabetes specialists.
In total, 510 type 2 diabetes patients from 116 out-
patient clinics were included. Refusal rates were unknown.
Sixty-three patients were found to be in good glycaemic
control upon inclusion (HbA1c B 7%) and were therefore
excluded from analysis, resulting in a study population of
N = 447 in sub-optimal glycaemic control. Fifty-two per
cent of the patients (N = 233) received NPH insulin as
basal therapy prior to initiating insulin glargine, 29%
(N = 130) of the patients received premixed insulin and
19% (N = 84) received insulin detemir as basal therapy.
Of the total population, 240 patients (54%) also received
rapid-acting (meal-time related) insulin as co-therapy prior
to therapy optimisation.
Measures
Demographic and clinical data were obtained at baseline, 3
and 6 months by means of self report and included age,
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gender, weight, height, time since diagnosis, previous
medication use, hypoglycaemic episodes, the presence of
diabetes-related complications, and co-morbidities. HbA1c
and Fasting Blood Glucose (FBG), measured according to
DCCT standards were retrieved from the medical chart.
Adverse events were recorded by the treating physician,
treated accordingly and reported to the researchers.
HRQoL is a multi-dimensional concept [17], in this
study operationalised as a low level of diabetes symptom
distress and fear of hypoglycaemia and a high level of
emotional well-being.
Diabetes-related symptom distress was measured using
the revised version of the Diabetes Symptom Checklist
(DSC-r), that has been shown to have good psychometric
properties [18, 19]. The DSC-r consists of 34 items
grouped into eight symptom sub-scales: Hyperglycaemia,
Hypoglycaemia, Cognitive distress, Fatigue, Cardiovascu-
lar distress, Neuropathic pain, Neuropathic sensibility and
Ophthalmologic function. Each item asks about the pres-
ence of complaints (yes/no) and if present, to score the
level of distress on a 5-point Likert type scale (i.e. ‘Have
you experienced numbness in the hands?’ (yes/no), ‘How
troublesome was this symptom for you?’ (Likert scale)).
Scores are then transformed to a 0–100 score to obtain the
DSC-r total distress score, with higher scores indicating
more diabetes symptom distress. This transformation was
also applied to the DSC-r sub-scales.
The Dutch version of the 13 item Worry sub-scale of the
Hypoglycaemia Fear Survey (HFS-w) [20] was used to
measure worries about hypoglycaemia. To facilitate inter-
pretation of data, HFS-w scores were also transformed to a
0–100 scale, with higher scores indicating higher worry
about hypoglycaemia.
The WHO-5 well-being index [21], a validated 5-item
instrument, was used to assess general emotional well-
being. The WHO-5 covers positive mood (good spirits,
relaxation), vitality (being active and waking-up fresh and
rested), and general interests (being interested in things).
Item scores are summated to provide a total well-being
score, transformed to a 0–100 scale, with lower scores
indicating poorer well-being.
In the present study, the Cronbach’s alpha’s for the HFS,
DSC-r total score and WHO-5 were 0.88, 0.94 and 0.90,
respectively, confirming high internal consistency.
Statistical analyses
Generalised estimating equations (GEE) analysis was used
for all longitudinal analyses. To test whether HbA1c, fasting
blood glucose, hypoglycaemia, BMI, insulin dosage (insu-
lin glargine and rapid-acting insulin) and scores on HFS-w,
DSC-r and WHO-5 changed during the study period for the
total population, time was modelled as an independent
dummy variable and the outcome measure as dependent
variable. For these analyses, effect sizes (Cohen’s d) for
6 month follow-up scores compared to baseline scores were
calculated, to gain insight in clinical relevance.
To study whether improvement in HbA1c, by means of
intensifying insulin therapy was related to improvement in
HRQoL, GEE analyses were carried out with HbA1c as
independent variable and HFS-w score, DSC-r score and
WHO-5 score, respectively as dependent variable.
Variables with a right-skewed distribution (time since
diagnosis, the number of diabetes complications, the number
of co-morbidities, the number of symptomatic, nocturnal and
severe hypoglycaemic episodes during the past 3 months,
HFS-w total score and DSC-r total and sub-scores) were
transformed with a natural logarithm for the purpose of
statistical testing. In case of a right-skewed distribution, the
median, 25th and 75th percentiles are presented.
We have studied the following variables as potential
confounders: age, sex, time since diagnosis, BMI, the
number of diabetes-related complications and the number
of co-morbidities by adding them to the GEE model and
looking if the coefficient of the main independent variable
changed by more than ten per cent. Time-varying covari-
ates (BMI and the number of symptomatic, nocturnal and
severe hypoglycaemic episodes) were treated as such in the
analysis. In case confounding, existed analyses were cor-
rected for that specific variable. Moreover, we tested effect
modification for sex, as a stronger association between
glycaemic control and depression has previously been
observed in women [22]. In case of effect modification,
analyses were stratified for sex.
Observational studies run a high risk of missing data, due
to the naturalistic setting and low level of monitoring. The
present study was no exception; at the start of the study,
19% of patients had missing data on the HFS-w, 23% on the
DSC-r and 10% on the WHO-5. At 3 month follow-up,
these percentages increased to 35, 37 and 27%, respec-
tively. At 6 month follow-up they further increased to 42,
40 and 33%. Missing data were imputed using multiple
imputations [23, 24]. The imputation model consisted of
age, sex, time since diagnosis, the number of complications,
the number of co-morbidities, HbA1c, FBG, the number of
symptomatic, nocturnal and severe hypoglycaemic epi-
sodes, type of insulin used, and scores on the remaining two
HRQoL instruments. Five datasets were generated using
this technique. Analyses on these datasets were combined
using Rubin’s rules for multiple imputations [23].
Results
Baseline characteristics of the study population and chan-
ges over time in clinical and HRQoL-related outcome
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variables are presented in Table 1. At insulin therapy
optimisation, 382 (85%) patients received rapid-acting
insulin as co-therapy. At 3 months, this increased to 442
(99%) patients and remained unchanged at 6 months.
Two adverse events were related to glargine treatment;
one patient experienced an allergic reaction and another
patient was hospitalised as consequence of a severe hypo-
glycaemic episode. Prior to insulin therapy optimisation,
mean HbA1c for the total patient population was 8.8 ± 1.4%
which decreased to 8.0 ± 1.2% and 7.7 ± 1.3% at 3 and
6 month follow-up, respectively (P \ 0.001). Additionally,
FBG improved from 10.2 ± 3.7 mmol/l to 8.5 ± 2.8 and
8.4 ± 2.9 mmol/l (P \ 0.001). The number of symptomatic
hypoglycaemic events patients reported to have experienced
during the past 3 months decreased from a median of 3 (25th
percentile 0, 75th percentile 7) to 2 (0, 6; P = 0.042) at
3 month follow-up, after which it remained stable, though
statistical significance did not remain (median 2, 25th per-
centile 0, 75th percentile 6; p between baseline and 6 month
follow-up 0.052). The percentage of patients who had
experienced one or more symptomatic hypoglycaemic
event(s) decreased significantly during the follow-up period
Table 1 Description of
baseline population
characteristics and changes in
clinical and HRQoL outcomes
during the study period
Mean ± SD’s are presented for
variables with a normal
distribution. Median (25th
percentile, 75th percentile) are
presented for variables with a
right-skewed distribution.
P values are corrected for age,
education level, diabetes





the past month. BMI body mass
index, FBG fasting blood




w hypoglycaemia fear survey-
worry sub-scale, WHO-5 world
health organisation five well-
being index
a Pre-glargine treatment
*P with baseline \ 0.05
**P with baseline \ 0.001
Baseline 3 months 6 months
Demographics
N 447
Age 59 ± 11
Male/female 227/220
Diabetes duration (years) 11 (7,16)
N, % lower educated 223 (50%)
BMI (kg/m2) 31.6 ± 6.8 32.0 ± 6.9* 32.0 ± 6.8**
Number of complications 1 (0, 2)
Number of comorbidities 1 (0, 2)
HbA1c (%) 8.8 ± 1.4 8.0 ± 1.2** 7.7 ± 1.3**
FBG (mmol/l) 10.2 ± 3.7 8.5 ± 2.8** 8.4 ± 2.9**
Hypoglycaemic episodes during the past three months
Symptomatic 3 (0, 7) 0 (2, 6)* 0 (2, 6)
N, % 1 or more 330 (74%) 304 (68%) 298 (67%)*
Nocturnal 0 (0, 2) 0 (0, 1)* 0 (0, 0)*
N, % 1 or more 174 (39%) 131 (29%)* 108 (24%)*
Severe 0.2 ± 0.5 0.2 ± 0.5 0.1 ± 0.5
N, % 1 or more 48 (11%) 55 (12%) 41 (9%)
Insulin
IU NPHa 30 (22, 46)
IU mixa 62 (38, 88)
IU levemira 38 (24, 60)
IU rapid acting (54.5 ± 34.3a) 48 (32, 72) 52 ± 36 51 ± 37
IU glargine 42 (26, 60) 48 (26, 68) 42 (26, 70)
HRQoL outcome measures
DSC-r 14 (6, 26) 11 (4, 21)** 10 (4, 20)**
DSC-r sub-domains
Hyperglycemia 13 (6, 31) 6 (0, 19)** 6 (0, 19)*
Hypoglycemia 8 (0, 25) 8 (0, 25)** 8 (0, 17)*
Cognitive 13 (0, 31) 6 (0, 25)* 6 (0, 25)**
Fatigue 25 (6, 50) 19 (6, 44)** 19 (0, 38)**
Cardiovascular 6 (0, 19) 6 (0, 19)* 6 (0, 13)*
Neuropathic sensory 8 (0, 25) 4 (0, 17)* 4 (0, 21)*
Neuropathic pain 6 (0, 19) 6 (0, 19) 6 (0, 25)
Vision 5 (0, 20) 5 (0, 10)** 0 (0, 10)**
HFS-w 15 (4, 27) 12 (4, 29) 13 (4, 35)
WHO-5 56 ± 23 62 ± 23** 65 ± 22**
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from 74% to 67 and 67% (P = 0.044). The number of
nocturnal hypoglycaemic events significantly decreased
from 1.5 ± 3.9 to 1.0 ± 2.4 and 0.8 ± 2.1, respectively
(P = 0.001), along with the percentage of patients who had
experienced one or more nocturnal events (from 39% to 29
and 24%, respectively; P = 0.001). Eleven per cent of the
patients (n = 48) reported to have experienced at least one
severe hypoglycaemic event 3 months prior to glargine ini-
tiation. This percentage did not significantly change during
the study period.
The median number of symptoms patients reported on
the DSC-r at baseline was 13 (25th percentile 8, 75th
percentile 19). This decreased to 12 (6, 19) and 10 (5, 18)
at 3 and 6 months, respectively (P \ 0.001). The DSC-r
total distress score was already relatively low prior to
glargine initiation (median 14, 25th percentile 6, 25th
percentile 26) but nevertheless decreased at 3 (11, 4, 21)
and 6 months (10, 4, 20), respectively (Cohen’s d 0.27;
P \ 0.001). The largest improvements were observed in
the sub-domains Fatigue (from 25 (6, 50) to 19 (6, 44) and
19 (0, 38), respectively; Cohen’s d 0.29; P \ 0.001),
Cognitive distress (from 13 (0, 31) to 6 (0, 25) and 6 (0,
25); Cohen’s d 0.24; P \ 0.001) and Hyperglycaemia
(from 13 (6, 31) to 6 (0, 19) and 6 (0, 19); Cohen’s d 0.30;
P = 0.003).
Mean Worries about hypo’s (HFS-w) score showed a
slight, non-significant decrease during the study period
(from a median of 15 (25th percentile 4, 75th percentile 27)
to 12 (4, 29) and 13 (4, 35); Cohen’s d 0.17; P = 0.610).
Mean emotional well-being (WHO-5) score was
56 ± 23 at baseline, which improved to 62 ± 23 at 3 and
65 ± 22 at 6 month follow-up (Cohen’s d 0.39;
P \ 0.001).
Longitudinal analyses revealed a modest, statistically
significant association between change in HbA1c and
change in WHO-5 score (standardised B = -2.6, 95% CI:
-3.6 to -1.5; P \ 0.001, Table 2). Adjustment for
demographic variables (age, sex, educational level, time
since diagnosis, the number of diabetes complications and
the number of co-morbidities) and baseline WHO-5 score
showed that the association was still significant, albeit
somewhat lower (standardised B = -1.7 (95% CI: -2.6 to
-0.8; P \ 0.001). Further adjustment for hypoglycaemia
did not alter these coefficients (standardised B = -1.8
(95% CI: -2.7 to -0.8; P \ 0.001). For DSC-r total score,
the uncorrected coefficient was B = 1.4 (95% CI: 0.8 to
2.0; P \ 0.001). After correction for demographic vari-
ables and baseline DSC-r score, the association became
B = 1.0 (95% CI: 0.4 to 1.5; P = 0.010). Further adjust-
ment for hypoglycaemia did not change the coefficient
further. For the HFS-w, no significant association with
HbA1c was found.
Discussion
In this 6 month observational study conducted in multiple
secondary care practices in the Netherlands, significant
improvement in HbA1c was observed following insulin
therapy optimisation in sub-optimally controlled type 2
diabetes patients. However, mean HbA1c at study endpoint
was still sub-optimal. Also, a decrease in symptomatic and
nocturnal hypoglycaemia was observed, in line with pre-
vious findings [7]. Importantly, significant improvements
in two of the three chosen HRQOL outcomes were
observed. Diabetes symptom distress (DSC-r) scores were
relatively low at baseline compared to other studies [15,
25], but nevertheless improved slightly. Whether this
improvement is clinically relevant (4 points) is not clear,
but it does exceed previously reported changes in DSC-r
score at a follow-up period of one year, in the range of
-0.11–0.25 SD (the change in the present study was 0.28
SD) [26]. Cohen’s d for change in DSC-r total score was
0.27, which can be interpreted as a ‘small’ effect. Emo-
tional well-being improved 9.4 points on the WHO-5 well-
being index, close to a clinically relevant improvement of
10 points, as defined by the authors of the instrument [21].
Table 2 Longitudinal associations of HbA1c with emotional well-
being (WHO-5 score), diabetes symptom distress (DSC-r score) and
fear of hypoglycaemia (HFS-w score)
B HbA1c 95% CI P value
WHO-5
Model 1 -2.6 -3.6 to -1.5 \0.001
Model 2 -2.5 -3.7 to -1.3 \0.001
Model 3 -1.7 -2.6 to -0.8 \0.001
Model 4 -1.8 -2.7 to -0.8 \0.001
DSC-r
Model 1 1.4 0.8 to 2.0 \0.001
Model 2 1.2 0.5 to 1.9 0.003
Model 3 1.0 0.4 to 1.5 0.010
Model 4 1.0 0.4 to 1.6 0.006
HFS-w
Model 1 0.02 -1.02 to 1.07 0.962
Model 2 -0.1 -1.3 to 1.0 0.819
Model 3 -0.3 -1.3 to 0.8 0.597
Model 4 -0.2 -1.3 to 0.8 0.631
Model 1 unadjusted association
Model 2 adjusted for age, sex, time since diabetes diagnosis, educa-
tional level, the number of co-morbidities and the number of diabetes
complications
Model 3 further adjusted for baseline WHO-5 score, DSC-r score and
HFS-w score, respectively
Model 4 further adjusted for symptomatic, nocturnal and serious
hypoglycaemia
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Cohen’s d for WHO-5 improvement was 0.39, which can
be interpreted as a ‘moderate’ effect.
The results of our study confirm that glycaemic
improvement is associated with positive effects on patients’
HRQoL at least over the first 6 months. While statistical
significant longitudinal associations between HbA1c and
WHO-5 and DSC-r score were found, they were not strong.
However, the association remained, even after corrections
for demographic and clinical variables and hypoglycaemia.
To establish longer-term effects, further research is war-
ranted. We should of course recognize that establishing a
longitudinal association does not provide us with a mech-
anistic explanation or proof of causation. Physiological,
emotional and behavioural factors are likely to play a role.
The increase in emotional well-being might very well be
related to factors that are not measured in this study, such
as the increased sense of freedom patients may experience
with their new treatment regimen. At the end of the study,
almost all patients received insulin glargine and a rapid-
acting insulin analogue, allowing for more dietary freedom
in their daily life, which has previously been shown to
increase treatment satisfaction and quality of life in type 1
diabetes patients [27]. Unfortunately, the intensity of care
that patients received was not documented in the study.
When intensified insulin therapy is instituted, the amount
of visits is possibly increased, which may have contributed
to improved satisfaction with care and well-being.
The observational design of our study invokes four
noteworthy other limitations: A Hawthorne effect cannot
be excluded, missing data was present, the lack of blinding
and the lack of a control group. Another limitation of the
study is that refusal rates and reasons for refusal were not
documented. It would, however, seem very unlikely that
the observed improvements in emotional well-being fol-
lowing therapy optimisation at 3 months, sustained at
6 months are merely due to an expectancy effect, because
the observed decrease nearly reached clinical relevance,
defined as a change in WHO-5 score of 10 points [30].
Furthermore, missing data were addressed using a state of
the art technique [24].
Our findings add to the literature pointing at the complex
relation between glycaemic control (HbA1c) and patient-
reported outcomes. In this context, we should recognize that
HbA1c is not an instant measure of blood glucose, but rather
an indication of mean blood glucose values over a longer
period of time (6–8 weeks). While a high HbA1c is an
important risk factor for long-term vascular complications
in diabetes patients, HbA1c does not directly translate into
tangible symptoms, because it is a weighted measure of
mean blood glucose over the preceding 120 day period [28].
Indeed many patients are unaware of their HbA1c level [29].
More research on the subject is warranted, incorporating
measures of treatment burden and patient satisfaction [30].
Conclusions
In this study, an association is observed between improving
HbA1c, by optimising insulin therapy in type 2 diabetes
patients and improvement in HRQoL. A weak, yet signif-
icant longitudinal association was found between improved
HbA1c and emotional well-being. Our findings add to the
literature on the complex relationship between glycaemic
control and quality of life.
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